Breaking News

WuXi Biologics Completes EMA GMP Inspection

Becomes the first biologics company in China to do so

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The European Medicines Agency (EMA) has completed the Pre-Approval Inspection (PAI) of Wuxi Biologics’ cGMP drug substance (DS) and drug product (DP) manufacturing facilities for the production of TaiMed Biologics’ Trogarzo with no critical findings. WuXi Biologics will submit responses to the EMA inspection report in March 2019 and expects to obtain GMP certification for its facilities in May 2019.   According to the company, this is the first inspection of its kind in China. Upon complet...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters